Apollomics
PublicApollomics is now publicly traded
The data on this page reflects Apollomics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Private Placement
Aug 19, 2026
Total Funding Raised
$273.45M
Company Overview
Apollomics is a biopharmaceutical company that discovers and develops innovative oncology therapies, including targeted and immuno-oncology agents, to treat various cancers.
Sector
Biotech
AI Layer
Non-AI
Keywords
Apollomics Comparables
Compare Apollomics with similar companies based on industry and business-model similarity.
No public comparables are available for Apollomics. Request access to learn about comparables coverage.
Request accessApollomics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Placement | Aug 19, 2026 | ||||
| PIPE | May 8, 2024 | ||||
| PIPE | Mar 29, 2023 | ||||
| Series C | Nov 6, 2020 | ||||
| Series B | Jan 7, 2019 | ||||
Series A | Aug 29, 2016 |
Apollomics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| OrbiMed Asia | Series B, Series A |
| Yanchuang Capital | Series C |
| 招银国际金融有限公司 | Series B |
| OrbiMed | Series B |
| Ping An Capital | Series C |
Apollomics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access